AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]
Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]
AAVantgarde’s AAVB-039 gene therapy, targeting the root cause of Stargardt [...]
Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]